Thomas Meier - Santhera Pharmaceuticals CEO and Head of the Executive Management Team
| SPHDF Stock | USD 9.42 2.28 19.49% |
CEO
Dr. Thomas Meier, Ph.D., was Chief Executive Officer, Member of the Executive Management Board andDelegate of the Board of Santhera Pharmaceuticals Holding Ltd since April 4, 2017. He was Chief Executive Officer, Member of the Executive Management Board at Santhera Pharmaceuticals Holding AG since October 1, 2011. Prior to that, he served as Member of the Management Board and Chief Scientific Officer at the Company from 2004. He was founder and former Chief Executive Officer of MyoContract prior to the combination with Graffinity that led to the Company. In 1999, he became Independent Research Group Leader and Lecturer in the Department of Pharmacology and Neurobiology at the Biozentrum of the Universitaet Basel, where he established MyoContract. He received his Doctorate in Philosophy degree in Biology from Universitaet Basel, in 1992, and subsequently joined the University of Colorado Health Sciences Center. He is author of several papers in the field of neuromuscular research. He won the International Research Fellowship Award from the United States National Institutes of Health and has received a longterm fellowship from the Human Frontier Science Foundation. In 2007, he received the BioValley Basel Award for his contributions to the life sciences in the area. since 2017.
| Age | 61 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 41 61 906 89 50 |
| Web | https://www.santhera.com |
Santhera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4918) % which means that it has lost $0.4918 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (13.1615) %, meaning that it generated substantial loss on money invested by shareholders. Santhera Pharmaceuticals' management efficiency ratios could be used to measure how well Santhera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CEO Age | ||
| Stephen Stamp | Biodexa Pharmaceticals | 62 | |
| Alexandria Forbes | MeiraGTx Holdings PLC | 59 | |
Management Performance
| Return On Equity | -13.16 | |||
| Return On Asset | -0.49 |
Santhera Pharmaceuticals Leadership Team
Elected by the shareholders, the Santhera Pharmaceuticals' board of directors comprises two types of representatives: Santhera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santhera. The board's role is to monitor Santhera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Santhera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santhera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eva Kalias, Head Communications | ||
| Shabir MD, Chief Officer | ||
| FCMA CGMA, Chief Officer | ||
| Thomas Meier, CEO and Head of the Executive Management Team | ||
| Dario Eklund, Chief Officer | ||
| Gnther Metz, Head VP | ||
| Neville MD, Head Management | ||
| Sarah HolmesKlotz, Head Culture | ||
| Oliver Strub, Sr. VP, General Counsel and Secretary | ||
| Marc Schrader, Head Operations |
Santhera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Santhera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -13.16 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (386.18) % | |||
| Current Valuation | 60.45 M | |||
| Shares Outstanding | 61.81 M | |||
| Shares Owned By Insiders | 18.77 % | |||
| Shares Owned By Institutions | 3.50 % | |||
| Price To Earning | (6.80) X | |||
| Price To Book | 2.75 X | |||
| Price To Sales | 469.19 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Santhera Pink Sheet
Santhera Pharmaceuticals financial ratios help investors to determine whether Santhera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santhera with respect to the benefits of owning Santhera Pharmaceuticals security.